Flow Cytometry in Oncology and Immunology Global Market Report 2022: Innovation in Flow Cytometry Leading to Use of Next-Generation Flow Cytometers
29 nov. 2022 04h03 HE | Research and Markets
Dublin, Nov. 29, 2022 (GLOBE NEWSWIRE) -- The "Flow Cytometry in Oncology and Immunology Market - A Global Market and Regional: Focus on Offering, Technology, End User, Type, Application, and...
logo.png
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
28 nov. 2022 08h00 HE | Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
AIMLogo.jpg
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
15 nov. 2022 07h00 HE | AIM ImmunoTech Inc.
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...
Mendus AB: Mendus to report positive clinical and preclinical data in ovarian cancer at the European Society of Gynaecological Oncology 2022 Congress
17 oct. 2022 02h15 HE | Mendus AB
RESULTS UNDERPIN DCP-001’S POTENTIAL AS A NOVEL MAINTENANCE AND INTERVENTIONAL THERAPY IN A MAJOR SOLID TUMOR INDICATION Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on...
Mendus AB: Mendus presenterar positiva kliniska och prekliniska data vid behandling av äggstockscancer på European Society of Gynaecological Oncology 2022
17 oct. 2022 02h15 HE | Mendus AB
RESULTATEN STÖDJER POTENTIALEN FÖR MENDUS IMMUNTERAPIKANDIDAT DCP-001 FÖR SÅVÄL NY UNDERHÅLLSBEHANDLING SOM AKTIV BEHANDLING I EN BETYDANDE INDIKATION AV SOLIDA TUMÖRER Mendus AB (“Mendus” publ;...
Aprea logo 445pt.png
Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series
22 sept. 2022 18h00 HE | Aprea Therapeutics
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting...
Nouveau Logo communiqué de presse.JPG
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
12 sept. 2022 07h30 HE | Theratechnologies
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...
Nouveau Logo communiqué de presse.JPG
L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale
12 sept. 2022 07h30 HE | Theratechnologies
Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
TIP_link_300x300.jpg
Doxorubicin Market Revenue to Cross $1,983.40 million by 2028 to Rise at a Stellar CAGR of 6.1% by 2028 | Exclusive Research by The Insight Partners
12 juil. 2022 10h54 HE | The Insight Partners
New York, July 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Formulation,...
CancerLife, a Digital Health Company, With the Validation Institute, Announces Results of Its Phase 3 Trial That Raised EQ-5 Quality of Life (QOL) Scores by 14.3%
02 juin 2022 09h30 HE | CancerLife
PHILADELPHIA, June 02, 2022 (GLOBE NEWSWIRE) -- CancerLife, a digital therapeutics company with the Validation Institute, announced the results of its two-arm, fully randomized Phase 3 clinical...